Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Feb;63(2):287–292. doi: 10.1038/bjc.1991.67

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.

G Pichert 1, L M Jost 1, W Fierz 1, R A Stahel 1
PMCID: PMC1971775  PMID: 1997108

Abstract

The clinical and immune modulatory effects of interleukin-2 (IL-2) and interferon (INF) alfa-2a were examined in a phase II study in patients with metastatic renal cell carcinoma (six patients) and melanoma (eight patients). Treatment consisted in IL-2 3 MU/m2 continuous infusion days 1-4 and INF alfa-2a 6 MU/m2 subcutaneously day 1 and 4, both given on alternate weeks. Tumour response was assessed after four cycles of treatment or earlier, if necessary. Patients with stable disease or response were to be continued for another nine cycles or up to disease progression. The 14 patients received a total of 60 cycles of treatment. Major toxicities (WHO Grade III/IV) were fever, capillary leak syndrome with hypotension, nausea and vomiting, erythema with pruritus, leuco- and thrombopenia and sepsis with staphylococcus aureus. Five of 14 patients (36%) developed a self limiting autoimmune thyroiditis with HLA-DR expression on thyrocytes. Long term treatment toxicity was moderate with an average weight loss of 5% and an average fall in Karnofsky index of 10% compared to baseline. No responses were seen in renal cell carcinoma, two patients with melanoma had a partial and two a minor response with a duration of 1-7 months. Serial measurements of immune modulatory parameters showed a functional response to treatment with an increase of NK- and LAK-activity during the first two cycles, followed by a plateau and decrease during the third and fourth cycles. These findings were paralleled by a successive decline in treatment induced INF gamma response. These findings suggest, that alternative weekly treatment with IL-2 and INF alfa-2a results in an exhaustion of lytic capacity of NK- and LAK-cells and an attenuation of secondary cytokine release.

Full text

PDF
287

Images in this article

289Figure 2
on p.289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., Mier J. W., Parkinson D. R., Gould J. A., Berkman E. M., Kaplan M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988 Jun 16;318(24):1557–1563. doi: 10.1056/NEJM198806163182401. [DOI] [PubMed] [Google Scholar]
  2. Bar M. H., Sznol M., Atkins M. B., Ciobanu N., Micetich K. C., Boldt D. H., Margolin K. A., Aronson F. R., Rayner A. A., Hawkins M. J. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol. 1990 Jul;8(7):1138–1147. doi: 10.1200/JCO.1990.8.7.1138. [DOI] [PubMed] [Google Scholar]
  3. Brunda M. J., Bellantoni D., Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer. 1987 Sep 15;40(3):365–371. doi: 10.1002/ijc.2910400314. [DOI] [PubMed] [Google Scholar]
  4. Brunda M. J., Tarnowski D., Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer. 1986 May 15;37(5):787–793. doi: 10.1002/ijc.2910370522. [DOI] [PubMed] [Google Scholar]
  5. Dutcher J. P., Creekmore S., Weiss G. R., Margolin K., Markowitz A. B., Roper M., Parkinson D., Ciobanu N., Fisher R. I., Boldt D. H. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989 Apr;7(4):477–485. doi: 10.1200/JCO.1989.7.4.477. [DOI] [PubMed] [Google Scholar]
  6. Fidler I. J., Heicappell R., Saiki I., Grutter M. G., Horisberger M. A., Nuesch J. Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines. Cancer Res. 1987 Apr 15;47(8):2020–2027. [PubMed] [Google Scholar]
  7. Fisher R. I., Coltman C. A., Jr, Doroshow J. H., Rayner A. A., Hawkins M. J., Mier J. W., Wiernik P., McMannis J. D., Weiss G. R., Margolin K. A. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr;108(4):518–523. doi: 10.7326/0003-4819-108-4-518. [DOI] [PubMed] [Google Scholar]
  8. Golub S. H., D'Amore P., Rainey M. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst. 1982 May;68(5):711–717. [PubMed] [Google Scholar]
  9. Grimm E. A., Robb R. J., Roth J. A., Neckers L. M., Lachman L. B., Wilson D. J., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983 Oct 1;158(4):1356–1361. doi: 10.1084/jem.158.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hersey P., Hasic E., MacDonald M., Edwards A., Spurling A., Coates A. S., Milton G. W., McCarthy W. H. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer. 1985 Jun;51(6):815–826. doi: 10.1038/bjc.1985.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klempner M. S., Noring R., Mier J. W., Atkins M. B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990 Apr 5;322(14):959–965. doi: 10.1056/NEJM199004053221404. [DOI] [PubMed] [Google Scholar]
  12. Lee K. H., Talpaz M., Rothberg J. M., Murray J. L., Papadopoulos N., Plager C., Benjamin R., Levitt D., Gutterman J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol. 1989 Nov;7(11):1726–1732. doi: 10.1200/JCO.1989.7.11.1726. [DOI] [PubMed] [Google Scholar]
  13. Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  14. Pichert G., Jost L. M., Zöbeli L., Odermatt B., Pedia G., Stahel R. A. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer. 1990 Jul;62(1):100–104. doi: 10.1038/bjc.1990.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Quesada J. R., Rios A., Swanson D., Trown P., Gutterman J. U. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985 Nov;3(11):1522–1528. doi: 10.1200/JCO.1985.3.11.1522. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Lotze M. T., Mulé J. J. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988 Jun;108(6):853–864. doi: 10.7326/0003-4819-108-6-853. [DOI] [PubMed] [Google Scholar]
  17. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  18. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  19. Stahel R. A., Sculier J. P., Jost L. M., Delforge A., Bron D., Gmür J., Oelz O., Sauter C., Stryckmans P., Klastersky J. Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol. 1989 Jun;25(6):965–972. doi: 10.1016/0277-5379(89)90155-7. [DOI] [PubMed] [Google Scholar]
  20. Stötter H., Wiebke E. A., Tomita S., Belldegrun A., Topalian S., Rosenberg S. A., Lotze M. T. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol. 1989 Mar 1;142(5):1767–1773. [PubMed] [Google Scholar]
  21. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  22. Tokuda Y., Ebina N., Golub S. H. The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity. Cancer Immunol Immunother. 1989;30(4):205–212. doi: 10.1007/BF01665006. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES